Home/Pipeline/Dual Nav1.7/1.8 ASO

Dual Nav1.7/1.8 ASO

Chronic Pain

DiscoveryActive

Key Facts

Indication

Chronic Pain

Phase

Discovery

Status

Active

Company

Quiver Bioscience

About Quiver Bioscience

Quiver Bioscience is a private, pre-clinical stage biotech leveraging a proprietary, integrated platform of human disease models, scalable neural measurement technology, and AI to tackle the high failure rates in neurological drug development. The company has built a pipeline of wholly-owned antisense oligonucleotide (ASO) programs targeting genetically-validated pathways in chronic pain and developmental epileptic encephalopathies, and has secured strategic research collaborations with pharmaceutical partners. Positioned at the intersection of genetics, scalable biology, and computational power, Quiver aims to become a premier partner in translating target discovery into clinical candidates for CNS disorders.

View full company profile

Therapeutic Areas

Chronic Pain Developmental and Epileptic Encephalopathy Dup15q Syndrome Fragile X Syndrome Tuberous Sclerosis

Other Chronic Pain Drugs

Drug	Company	Phase	Status
SCI-160	SciSparc	Preclinical	Active
Injectrode Platform for Chronic Pain	Neuronoff	Pre-clinical	Active
Novel PNS System	Nervonik	First-in-Human Completed	Active
Pain Pipeline	Centrexion Therapeutics	Clinical Stage	Active
High-Definition Spinal Cord Stimulation	Micro-Leads	Unknown	Active
Precision Medicine for Pain	MindX Sciences	Commercial	Active
Chronic Pain Program	Current Surgical	Research	Active
N-19a	Neurocarrus	Pre-clinical	Active
Nav1.7 ASO	Quiver Bioscience	Discovery	Active
Nav1.8 ASO	Quiver Bioscience	Discovery	Active
TMS for Chronic Pain	Magstim	Commercial/Clinical Development	Active
Platform Enhancements	Nevro	R&D	Active